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Chronic ulcerative colitis is a premalignant condition and predisposes to adenocarcinoma of the colon.
The association between ulcerative colitis and colorectal cancer was first reported in 1920. Several
subsequent studies 2-5 have since confirmed ulcerative colitis as a predisposing cause of large bowel
cancer. The management of ulcerative colitis is never complete unless an appropriate surveillance
protocol is established6. The concept of screening high risk group for colon cancer is based on the fact
that cancers discovered and removed before they cause symptoms are more likely to be cured. Because
the prognosis after surgical treatment in colon cancer complicating ulcerative colitis is Duke’s stage
dependent, survival would be improved if colitis - cancer is diagnosed earlier7. Ulcerative colitis is
being more commonly diagnosed in our country and the period of follow-up is also increasing8. In
Pakistan true prevalence of this disease is unknown. In a large referral centre the incidence of ulcerative
colitis in patients presenting with rectal bleeding was reported to be as high as 25%9.The risk of cancer
in ulcerative colitis has been calculated to be 3-30 times that of the general population3,10. Duration of
colitis and extent of disease are major risk factors influencing risk of cancer4. Early age of onset, a
severe first attack and continuous activity of disease are other important risk factors11. Age and extent
of disease at diagnosis are strong and independent risk factors for colorectal cancer; the absolute risk of
colorectal cancer 35 years after diagnosis was 30% for patients with pancolitis and 40% for those given
this diagnosis at less than 15 years of age12. Several studies have reported that patients with left sided
colitis or proctitis have a relatively lower risk of colorectal cancer than those with pancolitis13,14. In
younger groups, however, and especially among patients 15 to 29 years of age at the time of diagnosis,
left sided colitis entailed a relative risk of colorectal cancer that was close to that for pancolitis. In older
group the relative risk was close to 1.012. We have a close system of follow-up at our institution and
patients with history of active chronic ulcerative colitis of 5 years or more are closely followed
regarding activity of disease. Traditional screening methods used for other high risk groups are not
applicable to patients with ulcerative colitis. Tests for occult blood in the stool are useless because
blood is commonly present in the stool of ulcerative colitis patient 16. Serum levels of CEA (carcinoma
embryonic antigen) are also often elevated in these patients15. Barium enema is not suitable for
surveillance because the meticulous technique needed to detect small abnormalities are generally not
available 17. Dysplasia is present in over 80% of colectomy specimen in which a carcinoma is found18.
Colonoscopy has emerged as a major technique providing a magnified view and tissue sampling
capability for the entire colon19. In a review by Dobbins dysplasia was found in 88% of 108 colectomy
specimens containing cancers while dysplasia was noted in the rectum in 66% of these cases20.
Histologically dysplasia is classified as negative, indefinite and positive with positives divided into low
and high grade classes. Dysplasia appears to be apre-neoplastic abnormality but the timing of its
evolution and possible regression remain to be elucidated21. The reported incidence of dysplasia and
cancer complicating ulcerative colitis in Pakistan is low mainly because of shorter duration of follow
up and possibly due to a higher incidence of left sided colitis22. Biopsies should be performed on
suspicious pseudopolyps and adenomatous polyps should be removed. In seeking dysplasia which is
found most often in flat mucosa, about 12 biopsies should be taken systematically through the colon at
10 cms intervals. The most common approach is to take biopsies from caecum, ascending colon,
hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon and rectum.

Biopsies from areas not actually inflamed are more easily interpreted for dysplasia2’. Based on
multiple studies about one-third to one-half of patients with high grade dysplasia have a synchronous
occult cancer23. Risk of cancer will not be affected by surveillance but early diagnosis would make
them more amenable to treatment. The design of most surveillance programmes is essentially similar
with variation in recommended frequency of colonoscopy and sigmoidos copy with mucosal biopsies.
Surveillance need not be instituted before 7-8 years in pancolitis and 15 years in disease limited to left
colon. Ileoproctostomy for severe pancolitis should be included in a surveillance programme.
Pathologist experienced in interpreting dysplasias is essential for such a programem. Optimal timings
are far from established. In many programmes colonoscopy every 2-3 years with annual sigmoidoscopy
is recommended, others prefer annual colonoscopy. High grade dysplasia or any dysplasia associated
with a lesion such as mass or stricture is a strong indication for colectomy and should be confirmed by
repeat biopsy20,21. A difficult area is follow-up of low grade dysplasia in flat mucosa20. It needs
frequent examination and aggressive treatment. A repeat procedure in the first 3-6 months is warranted
since low grade dysplasias in flat mucosa may be accompanied by invasive carcinomas either at the site
or elsewhere in 10-15% of these individuals 20. It is felt that wider awareness amongst doctors working
with inflammatory bowel diseases would help to sort out some of these contentious issues.
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